# An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients

> **NCT04662931** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 140 (actual)

## Conditions studied

- Sickle Cell Disease (SCD)

## Interventions

- **DRUG:** crizanlizumab

## Key facts

- **NCT ID:** NCT04662931
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2024-02-14
- **Final completion:** 2024-02-14
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04662931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04662931, "An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04662931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*